![]() One of PepGen’s lead indications, DMD is a devastating genetic neuromuscular disorder affecting one in 3,500-5,000 male births around the world. “I am delighted to see our progress validated by support from top-tier investors, and look forward to seeing translation into the clinic.” “PepGen’s cell-penetrating peptide (CPP) technology represents an important step change in that we have succeeded in optimizing cellular uptake whilst simultaneously engineering out the safety signals that historically impacted earlier attempts at this approach,” said PepGen co-founder Matthew Wood, professor of neuroscience at the University of Oxford. PepGen’s proprietary PPMO technology will dramatically enhance delivery of oligonucleotides to key tissues, while also improving safety compared with competing therapies. ![]() ![]() PepGen will use the funding to advance into the clinic their next-generation cell-penetrating peptides conjugated to phosphorodiamidate morpholino oligomers (PPMOs) that are designed to correct genetic defects in diseases with high unmet medical need. The University of Oxford and CureDuchenne Ventures, a leading patient advocacy group, also participated in the round. ![]() 09, 2020 (GLOBE NEWSWIRE) - PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |